Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
Should have gotten out when
hit 45. This company has yet to produce an actual product in its 15 year history. It is a long time loser.
Add a reply...
Latest StockTalks »
people get SRPT breaking news and analysis by email alert.
Get email alerts on SRPT »
Sarepta Therapeutics, Inc.
Get latest price
From other sites
Sarepta Therapeutics : Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments
at 4-traders.com (Mar 24, 2015)
10 Biotech Stories You Might've Missed This Week
at Benzinga.com (Jan 15, 2015)
Chimerix tackles Ebola outbreak
at CNBC.com (Jan 13, 2015)
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
at Benzinga.com (Jan 13, 2015)
Stocks Hitting 52-Week Lows
at Benzinga.com (Jan 12, 2015)
Xignite quote data
© 2015 Seeking Alpha